NRXP Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
1.1M
+3.1%
1.1M
+8.6%
983.0K
+306.2%
242.0K
0
Cost of Revenue
675.0K
+7.0%
631.0K
+54.7%
408.0K
+320.6%
97.0K
0
Gross Profit
426.0K
-2.5%
437.0K
-24.0%
575.0K
+296.6%
145.0K
0
Operating Expenses
6.9M
+33.8%
5.2M
-0.4%
5.2M
+24.7%
4.2M
+11.8%
3.7M
R&D
2.1M
+61.7%
1.3M
+134.6%
558.0K
-61.0%
1.4M
+44.8%
987.0K
SG&A
4.7M
+24.4%
3.8M
-16.5%
4.6M
+62.7%
2.8M
+2.4%
2.7M
Operating Income
-6505000
-37.2%
-4742000
-2.6%
-4624000
-14.9%
-4024000
-7.9%
-3730000
EBITDA
-6430000
-37.2%
-4685000
-2.9%
-4552000
-11.3%
-4090000
-9.6%
-3731000
Net Income
-16520000
-1055.2%
-1430000
-497.2%
360.0K
+106.1%
-5890000
+66.5%
-17581000
EPS (Basic)
$-0.44
-1000.0%
$-0.04
-500.0%
$0.01
+103.7%
$-0.27
+72.4%
$-0.98
EPS (Diluted)
$-0.44
-1000.0%
$-0.04
-500.0%
$0.01
+103.7%
$-0.27
+72.4%
$-0.98
Shares (Diluted)
37.6M
+16.5%
32.3M
+11.3%
29.0M
+30.6%
22.2M
+24.0%
17.9M
NRX Pharmaceuticals (NRXP) โ€” Financials